Hoque Monira, Abbassi Ramzi H, Froio Danielle, Man Jennifer, Johns Terrance G, Stringer Brett W, Day Bryan W, Pajic Marina, Kassiou Michael, Munoz Lenka
The University of Sydney, Faculty of Medicine and Health, Charles Perkins Centre, NSW 2006, Australia.
The Kinghorn Cancer Centre, The Garvan Institute of Medical Research, Sydney, NSW 2010, Australia.
Pharmacol Res. 2018 Aug;134:166-178. doi: 10.1016/j.phrs.2018.06.023. Epub 2018 Jun 23.
In the field of kinase inhibitors for applications in cancer research, tubulin is emerging as a targeted cellular protein that can significantly contribute to their activities. However, investigation of kinase inhibitors beyond the kinome is an area often neglected. Herein, we describe the results of pharmacological studies using drugs targeting kinases, tubulin or both. A key finding is that if cells are treated with a kinase inhibitor unintentionally targeting tubulin, their characteristic shape will diminish within a short timeframe. These changes in cell morphology are not seen when cells are treated with bona fide kinase inhibitors that do not directly target tubulin. Thus, early changes in cell morphology upon treatments are a strong indication that the inhibitor is directly targeting tubulin. Recognizing tubulin as a target of kinase inhibitors will build confidence in the future mechanistic studies using kinase inhibitors.
在用于癌症研究的激酶抑制剂领域,微管蛋白正成为一种靶向细胞蛋白,它对激酶抑制剂的活性有显著贡献。然而,对激酶组以外的激酶抑制剂的研究是一个常被忽视的领域。在此,我们描述了使用靶向激酶、微管蛋白或两者的药物进行的药理学研究结果。一个关键发现是,如果用意外靶向微管蛋白的激酶抑制剂处理细胞,其特征形状会在短时间内消失。当用不直接靶向微管蛋白的真正激酶抑制剂处理细胞时,不会出现这些细胞形态变化。因此,处理后细胞形态的早期变化强烈表明该抑制剂直接靶向微管蛋白。将微管蛋白识别为激酶抑制剂的靶点将为未来使用激酶抑制剂的机制研究建立信心。